Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease.

Faura J, Bustamante A, Penalba A, Giralt D, Simats A, Martínez-Sáez E, Alcolea D, Fortea J, Lleó A, Teunissen CE, van der Flier WM, Ibañez L, Harari O, Cruchaga C, Hernández-Guillamón M, Delgado P, Montaner J.

J Alzheimers Dis. 2020;73(4):1585-1595. doi: 10.3233/JAD-190753.

PMID:
31958084
2.

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2020 Jan 18. doi: 10.1007/s00401-019-02107-8. [Epub ahead of print]

PMID:
31955222
3.

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.

Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, Hye A, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Engelborghs S, Sleegers K, Bordet R, Ramit L, Kettunen P, Tsolaki M, Verhey F, Alcolea D, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement (N Y). 2019 Dec 18;5:933-938. doi: 10.1016/j.trci.2019.11.001. eCollection 2019.

4.

Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease.

Cantero JL, Atienza M, Lage C, Zaborszky L, Vilaplana E, Lopez-Garcia S, Pozueta A, Rodriguez-Rodriguez E, Blesa R, Alcolea D, Lleo A, Sanchez-Juan P, Fortea J; Alzheimer’s Disease Neuroimaging Initiative.

Cereb Cortex. 2019 Dec 4. pii: bhz224. doi: 10.1093/cercor/bhz224. [Epub ahead of print]

PMID:
31799623
5.

APP-derived peptides reflect neurodegeneration in frontotemporal dementia.

Illán-Gala I, Pegueroles J, Montal V, Alcolea D, Vilaplana E, Bejanin A, Borrego-Écija S, Sampedro F, Subirana A, Sánchez-Saudinós MB, Rojas-García R, Vanderstichele H, Blesa R, Clarimón J, Antonell A, Lladó A, Sánchez-Valle R, Fortea J, Lleó A.

Ann Clin Transl Neurol. 2019 Dec;6(12):2518-2530. doi: 10.1002/acn3.50948. Epub 2019 Dec 2.

6.

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?

Veerabhadrappa B, Delaby C, Hirtz C, Vialaret J, Alcolea D, Lleó A, Fortea J, Santosh MS, Choubey S, Lehmann S.

Crit Rev Clin Lab Sci. 2020 Mar;57(2):99-113. doi: 10.1080/10408363.2019.1678011. Epub 2019 Oct 29.

PMID:
31661652
7.

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.

Alcolea D, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I, Ribosa-Nogué R, Sala I, Sánchez-Saudinós MB, Videla L, Subirana A, Benejam B, Valldeneu S, Fernández S, Estellés T, Altuna M, Santos-Santos M, García-Losada L, Bejanin A, Pegueroles J, Montal V, Vilaplana E, Belbin O, Dols-Icardo O, Sirisi S, Querol-Vilaseca M, Cervera-Carles L, Muñoz L, Núñez R, Torres S, Camacho MV, Carrió I, Giménez S, Delaby C, Rojas-Garcia R, Turon-Sans J, Pagonabarraga J, Jiménez A, Blesa R, Fortea J, Lleó A.

Alzheimers Dement (N Y). 2019 Oct 14;5:597-609. doi: 10.1016/j.trci.2019.09.005. eCollection 2019.

8.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Nov;15(11):1478-1488. doi: 10.1016/j.jalz.2019.06.4951. Epub 2019 Sep 5.

9.

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Alcolea D, Pegueroles J, Muñoz L, Camacho V, López-Mora D, Fernández-León A, Le Bastard N, Huyck E, Nadal A, Olmedo V, Sampedro F, Montal V, Vilaplana E, Clarimón J, Blesa R, Fortea J, Lleó A.

Ann Clin Transl Neurol. 2019 Sep;6(9):1815-1824. doi: 10.1002/acn3.50873. Epub 2019 Aug 28.

10.

The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, Bradley J, Budde J, Ibanez L, Fernandez MV, Blennow K, Zetterberg H, Heslegrave A, Johansson PM, Svensson J, Nellgård B, Lleo A, Alcolea D, Clarimon J, Rami L, Molinuevo JL, Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Ewers M, Harari O, Haass C, Brett TJ, Benitez BA, Karch CM, Piccio L, Cruchaga C.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaau2291. doi: 10.1126/scitranslmed.aau2291.

PMID:
31413141
11.

Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis.

Esteve P, Rueda-Carrasco J, Inés Mateo M, Martin-Bermejo MJ, Draffin J, Pereyra G, Sandonís Á, Crespo I, Moreno I, Aso E, Garcia-Esparcia P, Gomez-Tortosa E, Rábano A, Fortea J, Alcolea D, Lleo A, Heneka MT, Valpuesta JM, Esteban JA, Ferrer I, Domínguez M, Bovolenta P.

Nat Neurosci. 2019 Aug;22(8):1258-1268. doi: 10.1038/s41593-019-0432-1. Epub 2019 Jul 15.

PMID:
31308530
12.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27. Erratum in: Acta Neuropathol. 2020 Jan 18;:.

13.

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.

Morenas-Rodríguez E, Alcolea D, Suárez-Calvet M, Muñoz-Llahuna L, Vilaplana E, Sala I, Subirana A, Querol-Vilaseca M, Carmona-Iragui M, Illán-Gala I, Ribosa-Nogué R, Blesa R, Haass C, Fortea J, Lleó A.

Sci Rep. 2019 May 24;9(1):7803. doi: 10.1038/s41598-019-44173-8.

14.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
15.

Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy.

Illán-Gala I, Montal V, Borrego-Écija S, Vilaplana E, Pegueroles J, Alcolea D, Sánchez-Saudinós B, Clarimón J, Turón-Sans J, Bargalló N, González-Ortiz S, Rosen HJ, Gorno-Tempini ML, Miller BL, Lladó A, Rojas-García R, Blesa R, Sánchez-Valle R, Lleó A, Fortea J; Catalan Frontotemporal Dementia Initiative (CATFI) and the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI).

Brain. 2019 Apr 1;142(4):1121-1133. doi: 10.1093/brain/awz031.

16.

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, Rami L, Lladó A, Molinuevo JL, Tainta M, Clarimón J, Spires-Jones T, Blesa R, Fortea J, Martínez-Lage P, Sánchez-Valle R, Sabidó E, Bayés À, Belbin O.

Mol Cell Proteomics. 2019 Mar;18(3):546-560. doi: 10.1074/mcp.RA118.001290. Epub 2019 Jan 3.

17.

Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform.

Delaby C, Muñoz L, Torres S, Nadal A, Le Bastard N, Lehmann S, Lleó A, Alcolea D.

Clin Chim Acta. 2019 Mar;490:98-101. doi: 10.1016/j.cca.2018.12.021. Epub 2018 Dec 20.

PMID:
30579960
18.

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study.

Pegueroles J, Jiménez A, Vilaplana E, Montal V, Carmona-Iragui M, Pané A, Alcolea D, Videla L, Casajoana A, Clarimón J, Ortega E, Vidal J, Blesa R, Lleó A, Fortea J; Alzheimer's Disease Neuroimaging Initiative.

Oncotarget. 2018 Oct 5;9(78):34691-34698. doi: 10.18632/oncotarget.26162. eCollection 2018 Oct 5.

19.

Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

Ramos de Matos M, Ferreira C, Herukka SK, Soininen H, Janeiro A, Santana I, Baldeiras I, Almeida MR, Lleó A, Dols-Icardo O, Alcolea D, Benussi L, Binetti G, Paterlini A, Ghidoni R, Nacmias B, Meulenbroek O, van Waalwijk van Doorn LJC, Kuiperi HBJ, Hausner L, Waldemar G, Simonsen AH, Tsolaki M, Gkatzima O, Resende de Oliveira C, Verbeek MM, Clarimon J, Hiltunen M, de Mendonça A, Martins M.

J Alzheimers Dis. 2018;66(2):639-652. doi: 10.3233/JAD-180512.

PMID:
30320580
20.

Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.

Alcolea D, Irwin DJ, Illán-Gala I, Muñoz L, Clarimón J, McMillan CT, Fortea J, Blesa R, Lee EB, Trojanowski JQ, Grossman M, Lleó A.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):180-186. doi: 10.1136/jnnp-2018-318993. Epub 2018 Oct 8.

21.

CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.

Illán-Gala I, Alcolea D, Montal V, Dols-Icardo O, Muñoz L, de Luna N, Turón-Sans J, Cortés-Vicente E, Sánchez-Saudinós MB, Subirana A, Sala I, Blesa R, Clarimón J, Fortea J, Rojas-García R, Lleó A.

Neurology. 2018 Oct 23;91(17):e1619-e1628. doi: 10.1212/WNL.0000000000006383. Epub 2018 Oct 5.

PMID:
30291183
22.

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease.

Perea JR, Lleó A, Alcolea D, Fortea J, Ávila J, Bolós M.

Front Neurosci. 2018 Sep 7;12:609. doi: 10.3389/fnins.2018.00609. eCollection 2018.

23.

Challenges associated with biomarker-based classification systems for Alzheimer's disease.

Illán-Gala I, Pegueroles J, Montal V, Vilaplana E, Carmona-Iragui M, Alcolea D, Dickerson BC, Sánchez-Valle R, de Leon MJ, Blesa R, Lleó A, Fortea J.

Alzheimers Dement (Amst). 2018 Apr 21;10:346-357. doi: 10.1016/j.dadm.2018.03.004. eCollection 2018.

24.

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, Alcolea D, Pegueroles J, Muñoz L, Belbin O, de Leon MJ, Maceski AM, Hirtz C, Clarimón J, Videla S, Delaby C, Lehmann S, Blesa R, Lleó A.

Lancet Neurol. 2018 Oct;17(10):860-869. doi: 10.1016/S1474-4422(18)30285-0. Epub 2018 Aug 29.

PMID:
30172624
25.

Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation.

Morenas-Rodríguez E, Sala I, Subirana A, Pascual-Goñi E, Sánchez-Saudinós MB, Alcolea D, Illán-Gala I, Carmona-Iragui M, Ribosa-Nogué R, Camacho V, Blesa R, Fortea J, Lleó A.

J Alzheimers Dis. 2018;64(2):505-513. doi: 10.3233/JAD-180167.

PMID:
29889064
26.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
27.

Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease.

Cantero JL, Atienza M, Sanchez-Juan P, Rodriguez-Rodriguez E, Vazquez-Higuera JL, Pozueta A, Gonzalez-Suarez A, Vilaplana E, Pegueroles J, Montal V, Blesa R, Alcolea D, Lleo A, Fortea J.

Neurobiol Aging. 2018 Apr;64:58-67. doi: 10.1016/j.neurobiolaging.2017.12.010. Epub 2017 Dec 20.

PMID:
29331877
28.

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease.

Jimenez A, Pegueroles J, Carmona-Iragui M, Vilaplana E, Montal V, Alcolea D, Videla L, Illán-Gala I, Pané A, Casajoana A, Belbin O, Clarimón J, Moizé V, Vidal J, Lleó A, Fortea J, Blesa R; Alzheimer's Disease Neuroimaging Initiative.

Oncotarget. 2017 Oct 31;8(62):104706-104716. doi: 10.18632/oncotarget.22218. eCollection 2017 Dec 1.

29.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H.

JAMA Psychiatry. 2018 Jan 1;75(1):84-95. doi: 10.1001/jamapsychiatry.2017.3391. Erratum in: JAMA Psychiatry. 2018 Mar 1;75(3):303.

30.

Cortical microstructural changes along the Alzheimer's disease continuum.

Montal V, Vilaplana E, Alcolea D, Pegueroles J, Pasternak O, González-Ortiz S, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Ribosa-Nogué R, Sala I, Sánchez-Saudinós MB, García-Sebastian M, Villanúa J, Izagirre A, Estanga A, Ecay-Torres M, Iriondo A, Clerigue M, Tainta M, Pozueta A, González A, Martínez-Heras E, Llufriu S, Blesa R, Sanchez-Juan P, Martínez-Lage P, Lleó A, Fortea J.

Alzheimers Dement. 2018 Mar;14(3):340-351. doi: 10.1016/j.jalz.2017.09.013. Epub 2017 Oct 31.

PMID:
29080407
31.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27. Review.

32.

The pitfalls of biomarker-based classification schemes.

Illán-Gala I, Vilaplana E, Pegueroles J, Montal V, Alcolea D, Blesa R, Lleó A, Fortea J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 Sep;13(9):1072-1074. doi: 10.1016/j.jalz.2017.06.002. Epub 2017 Jul 10. No abstract available.

PMID:
28704640
33.

CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.

Alcolea D, Vilaplana E, Suárez-Calvet M, Illán-Gala I, Blesa R, Clarimón J, Lladó A, Sánchez-Valle R, Molinuevo JL, García-Ribas G, Compta Y, Martí MJ, Piñol-Ripoll G, Amer-Ferrer G, Noguera A, García-Martín A, Fortea J, Lleó A.

Neurology. 2017 Jul 11;89(2):178-188. doi: 10.1212/WNL.0000000000004088. Epub 2017 Jun 7.

PMID:
28592456
34.

Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.

Sala I, Illán-Gala I, Alcolea D, Sánchez-Saudinós MB, Salgado SA, Morenas-Rodríguez E, Subirana A, Videla L, Clarimón J, Carmona-Iragui M, Ribosa-Nogué R, Blesa R, Fortea J, Lleó A.

J Alzheimers Dis. 2017;58(3):909-918. doi: 10.3233/JAD-170073.

PMID:
28527215
35.

The frequency and influence of dementia risk factors in prodromal Alzheimer's disease.

Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, De Roeck EE, Tsolaki M, Freund-Levi Y, Johannsen P, Vandenberghe R, Lleó A, Alcolea D, Frisoni GB, Galluzzi S, Nobili F, Morbelli S, Drzezga A, Didic M, van Berckel BN, Salmon E, Bastin C, Dauby S, Santana I, Baldeiras I, de Mendonça A, Silva D, Wallin A, Nordlund A, Coloma PM, Wientzek A, Alexander M, Novak GP, Gordon MF; Alzheimer's Disease Neuroimaging Initiative, Wallin ÅK, Hampel H, Soininen H, Herukka SK, Scheltens P, Verhey FR, Visser PJ.

Neurobiol Aging. 2017 Aug;56:33-40. doi: 10.1016/j.neurobiolaging.2017.03.034. Epub 2017 Apr 8.

PMID:
28482212
36.

Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.

Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernández S, Videla L, Sala I, Sánchez-Saudinós MB, Morenas-Rodriguez E, Ribosa-Nogué R, Illán-Gala I, Gonzalez-Ortiz S, Clarimón J, Schmitt F, Powell DK, Bosch B, Lladó A, Rafii MS, Head E, Molinuevo JL, Blesa R, Videla S, Lleó A, Sánchez-Valle R, Fortea J.

Alzheimers Dement. 2017 Nov;13(11):1251-1260. doi: 10.1016/j.jalz.2017.03.007. Epub 2017 Apr 29.

37.

Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum.

Cervera-Carles L, Alcolea D, Estanga A, Ecay-Torres M, Izagirre A, Clerigué M, García-Sebastián M, Villanúa J, Escalas C, Blesa R, Martínez-Lage P, Lleó A, Fortea J, Clarimón J.

Neurobiol Aging. 2017 May;53:192.e1-192.e4. doi: 10.1016/j.neurobiolaging.2016.12.009. Epub 2016 Dec 22.

PMID:
28089353
38.

A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk.

Tell-Marti G, Puig-Butille JA, Potrony M, Plana E, Badenas C, Antonell A, Sanchez-Valle R, Molinuevo JL, Lleó A, Alcolea D, Fortea J, Fernández-Santiago R, Clarimón J, Lladó A, Puig S.

J Alzheimers Dis. 2017;56(3):1065-1074. doi: 10.3233/JAD-161113.

39.

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.

Carmona-Iragui M, Santos T, Videla S, Fernández S, Benejam B, Videla L, Alcolea D, Blennow K, Blesa R, Lleó A, Fortea J.

J Alzheimers Dis. 2017;55(4):1489-1496. doi: 10.3233/JAD-160827.

PMID:
27858714
40.

Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid.

Gamir-Morralla A, Belbin O, Fortea J, Alcolea D, Ferrer I, Lleó A, Iglesias T.

J Alzheimers Dis. 2017;55(4):1327-1333. doi: 10.3233/JAD-160639.

41.

Longitudinal brain structural changes in preclinical Alzheimer's disease.

Pegueroles J, Vilaplana E, Montal V, Sampedro F, Alcolea D, Carmona-Iragui M, Clarimon J, Blesa R, Lleó A, Fortea J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 May;13(5):499-509. doi: 10.1016/j.jalz.2016.08.010. Epub 2016 Sep 28.

PMID:
27693189
42.

CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.

Dangla-Valls A, Molinuevo JL, Altirriba J, Sánchez-Valle R, Alcolea D, Fortea J, Rami L, Balasa M, Muñoz-García C, Ezquerra M, Fernández-Santiago R, Lleó A, Lladó A, Antonell A.

Mol Neurobiol. 2017 Nov;54(9):6647-6654. doi: 10.1007/s12035-016-0106-x. Epub 2016 Oct 13.

PMID:
27738874
43.

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations.

Cosín-Tomás M, Antonell A, Lladó A, Alcolea D, Fortea J, Ezquerra M, Lleó A, Martí MJ, Pallàs M, Sanchez-Valle R, Molinuevo JL, Sanfeliu C, Kaliman P.

Mol Neurobiol. 2017 Sep;54(7):5550-5562. doi: 10.1007/s12035-016-0088-8. Epub 2016 Sep 8.

PMID:
27631879
44.

Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly.

Varga AW, Wohlleber ME, Giménez S, Romero S, Alonso JF, Ducca EL, Kam K, Lewis C, Tanzi EB, Tweardy S, Kishi A, Parekh A, Fischer E, Gumb T, Alcolea D, Fortea J, Lleó A, Blennow K, Zetterberg H, Mosconi L, Glodzik L, Pirraglia E, Burschtin OE, de Leon MJ, Rapoport DM, Lu SE, Ayappa I, Osorio RS.

Sleep. 2016 Nov 1;39(11):2041-2048.

45.

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C.

EMBO Mol Med. 2016 May 2;8(5):466-76. doi: 10.15252/emmm.201506123. Print 2016 May.

46.

Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.

Morenas-Rodríguez E, Cervera-Carles L, Vilaplana E, Alcolea D, Carmona-Iragui M, Dols-Icardo O, Ribosa-Nogué R, Muñoz-Llahuna L, Sala I, Belén Sánchez-Saudinós M, Blesa R, Clarimón J, Fortea J, Lleó A.

J Alzheimers Dis. 2016;50(2):539-46. doi: 10.3233/JAD-150746.

PMID:
26682689
47.

Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.

Carmona-Iragui M, Fernández-Arcos A, Alcolea D, Piazza F, Morenas-Rodriguez E, Antón-Aguirre S, Sala I, Clarimon J, Dols-Icardo O, Camacho V, Sampedro F, Munuera J, Nuñez-Marin F, Lleó A, Fortea J, Gómez-Ansón B, Blesa R.

J Alzheimers Dis. 2016;50(1):1-7. doi: 10.3233/JAD-150614.

PMID:
26639966
48.

Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases.

Cervera-Carles L, Pagonabarraga J, Pascual-Sedano B, Pastor P, Campolongo A, Fortea J, Blesa R, Alcolea D, Morenas-Rodríguez E, Sala I, Lleó A, Kulisevsky J, Clarimón J.

Am J Med Genet B Neuropsychiatr Genet. 2016 Mar;171B(2):175-80. doi: 10.1002/ajmg.b.32390. Epub 2015 Oct 9.

PMID:
26453547
49.

APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls.

Sampedro F, Vilaplana E, de Leon MJ, Alcolea D, Pegueroles J, Montal V, Carmona-Iragui M, Sala I, Sánchez-Saudinos MB, Antón-Aguirre S, Morenas-Rodríguez E, Camacho V, Falcón C, Pavía J, Ros D, Clarimón J, Blesa R, Lleó A, Fortea J; Alzheimer’s Disease Neuroimaging Initiative.

Oncotarget. 2015 Sep 29;6(29):26663-74. doi: 10.18632/oncotarget.5185.

50.

Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.

Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleó A, Hausner L, Molinuevo JL, Stomrud E, Farotti L, Ramakers IHGB, Tsolaki M, Skarsgård C, Åstrand R, Wallin A, Vyhnalek M, Holmber-Clausen M, Forlenza OV, Ghezzi L, Ingelsson M, Hoff EI, Roks G, de Mendonça A, Papma JM, Izagirre A, Taga M, Struyfs H, Alcolea DA, Frölich L, Balasa M, Minthon L, Twisk JWR, Persson S, Zetterberg H, van der Flier WM, Teunissen CE, Scheltens P, Blennow K.

Alzheimers Dement. 2016 Feb;12(2):154-163. doi: 10.1016/j.jalz.2015.08.003. Epub 2015 Sep 11.

PMID:
26368321

Supplemental Content

Loading ...
Support Center